Sarah Fenton

Dr. Sarah Fenton


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SFSarah Fenton
Sarah Fenton
DSDiana Saleiro
Diana Saleiro
Leonidas C PlataniasLeonidas C Platanias
Leonidas C Platanias
The interferons (IFNs) are essential components of the immune response against infections and malignancies. IFNs are potent promoters of the anti-tumor response, but there is also evidence that feedback mechanisms regulated by IFNs negatively control immune responses to avoid hyper-activation and limit inflammation. This balance of responses plays an important role in cancer surveillance, immunoediting and response to anticancer therapeutic approaches. Here we review the roles of both type I and type II IFNs on the control of the immune response against malignancies in the context of effects on both malignant cells and cells of the immune system in the tumor microenvironment.

1 December 2017 in Clinical Skin Cancer
Verified
Journal Article
Closed access
SFSarah Fenton
Sarah Fenton
JSJeffrey Sosman
Jeffrey Sosman
SCSUNANDANA CHANDRA
SUNANDANA CHANDRA

27 April 2020
Verified
Book Chapter
Open access
PDF file
SFSarah Fenton
Sarah Fenton
JSJeffrey Sosman
Jeffrey Sosman
SCSUNANDANA CHANDRA
SUNANDANA CHANDRA
Until fairly recently, treatment options for advanced melanoma have been relatively limited. Fortunately, the last decade has seen dramatic improvements in response rates and duration of overall survival after the introduction of checkpoint inhibitors and targeted therapies against mutations in the B-isoform of Raf (B-Raf) in metastatic or inoperable melanoma. This book chapter will discuss the role of wild type B-Raf in the cell, the changes induced by mutations in this protein, and current FDA approvals for targeted therapies against B-Raf, both as a monotherapy and in combination with MEK inhibitors. We will also summarize mechanisms of resistance against these targeted therapies as well as novel therapeutic regimens proposed to bypass resistance.